Trials - GoINPHARMA
Tuesday, 16 October 2018 - 20:39

Trials

Agreement on combo immunotherapy between Bristol-Myers Squibb and Compugen

US-based multinational Bristol-Myers Squibb (BMS) yesterday announced it plans to invest $12m in shares of the Israel-based biotech Compugen, in order to fund the clinical trials of investigational drug COM701, which will be tested in combination with immunotherapy Opdivo. Through…

Bausch Health announces good Phase III results from psoriasis therapy

Bausch Health–formerly known as Valeant–yesterday reported on a press release that the Journal of Drugs in Dermatology has published results from as many as two Phase III clinical trials, assessing corticosteroid Bryhali (halobetasol propionate) Lotion, 0.01% in patients with psoriasis….

Good Phase III results for Regeneron and Sanofi’s Dupixent

Regeneron Pharmaceuticals and Sanofi have announced at the  27th European Academy of Dermatology and Venereology (EADV) Congress, in Paris, positive results from a Phase III clinical trial assessing Dupixent (dupilumab) on adolescents with atopic dermatitis. The study was conducted on…

Excellent Phase III results for Gilead-Galapagos’ Filgotinib

Gilead announced yesterday, after trading had closed, that its investigational therapy Filgotinib (JAK-1 inhibitor), developed and licensed by Belgian biotech Galapagos, has reached all its primary and secondary endpoints in the early stages of the Phase III clinical trial Fitch-2….

Everything in place for first clinical trial with CRISPR technology

US-based biotech Vertex Pharmaceuticals, in partnership with Crispr Therapeutics, has started recruiting patients for the Phase I/II clinical trial with a treatment developed by the same Crispr Therapeutics–CTX001–for the treatment of beta-thalassemia. The FDA trial will be conducted in Regensburg…

Good Phase III results for Novartis’ cancer drug (breast cancer)

Novartis has announced today that its investigational BYL719  (alpelisib) therapy has reached its primary endpoints in the Phase III Solar-1 clinical trial. BYL719 is an alpha-specific PI3K inhibitor developed for the treatment of PIK3CA-mutant breast cancer, tested as intravenous infusion…

Excellent Phase III results from Zogenix (epilepsy), shares rise 30% in 2 days

California-based Zogenix has announced results from its Phase III Study 1504 clinical trial, designed to assess its investigational therapy ZX008 (fenfluramine hydrochloride), for the treatment of patients with Dravet syndrome, a rare form of epilepsy characterized by severe convulsive seizures….

Gilead-Galapagos’ Filgotinib shows efficacy in treating psoriatic arthritis

Gilead Sciences and Belgium-based biotech Galapagos yesterday announced, after Wall Street closed, data from the Phase II EQUATOR trial assessing filgotinib on 131 patients with psoriatic arthritis. The results are positive and demonstrate that filgotinib improves patients’ conditions after as…

Roche’s Tecentriq extends life expectancy of patients with lung cancer (NSCLC)

Switzerland-based Roche some hours ago announced results from the Phase III IMpower130 clinical trial, conducted on patients with non-squamous, non-small cell lung cancer (NSCLC) with Tecentriq (atezolizumab) vs conventional chemotherapy. The trial has shown that Roche’s therapy significantly increases patients’…

Hawaii bans some sunscreens as harmful for coral reefs

The Hawaii Government has passed a bill banning sunscreens containing Oxybenzone and Octinoxate, since these components are lethal for corals in seabed and in reefs. Approximately 6,000 pounds of sunscreen are deposited into the sea and may harm the fragile balance…

Genetics study on hair color origin and meaning

The scientific journal Nature Genetics has published an article reporting the results of a study performed by researchers Pirro G. Hysi and Ana M. Valdes, from King’s College London, on 300,000 people’s DNA, aimed at determining the genetic origins of…

Intercept shows another significant benefit of Ocaliva to people with PCB

New York-based biotech company Intercept Pharmaceuticals keeps momentum: its shares have risen over 15% since the beginning of the month. Intercept yesterday announced in a press release that the Phase III POISE clinical trial has demonstrated that Ocaliva (obeticholic acid)…

New data confirm that adult brain generates new neurons

The scientific journal Cell Stem Cell has published an article contradicting the almost universally shared theory that neurons are generated in the earliest life stages, yet their number does not increase during adulthood. A team of researchers led by scientist…

Rude awakening for immunotherapy sector

Last Friday’s news about the failed Phase III clinical trial with immunotherapy Keytruda in combination with Incyte’s cancer therapy epacadostat not only has wiped $4m from the US biotech’s capitalization over few hours, but has also risen much concern among…

Good Phase III results for Eli Lilly’s Cyramza (liver cancer)

US-based Eli Lilly yesterday announced the results from the Phase III REACH-2 clinical trial, conducted on patients with liver cancer (HCC) treated with Cyramza (ramucirumab) as a second-line treatment. The trial has delivered positive results and investors have soon rewarded…